Overview

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

Status:
Enrolling by invitation

Trial end date:
2026-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.

Phase:

Phase 3

Details

Lead Sponsor:

UCB Biopharma SRL